Overall survival (OS) results of phase III ARAMIS study of darolutamide (DARO) added to androgen deprivation therapy (ADT) for nonmetastatic castration-resistant prostate cancer (nmCRPC)

  • Karim Fizazi (Contributor)
  • Neal Shore (Contributor)
  • Tammela, T. (Contributor)
  • Albertas Ulys (Contributor)
  • Egils Vjaters (Contributor)
  • Sergey Polyakov (Contributor)
  • Mindaugas Jievaltas (Contributor)
  • Murilo Luz (Contributor)
  • Boris Alekseev (Contributor)
  • Iris Kuss (Contributor)
  • Marie-Aude Le Berre (Contributor)
  • Oana Petrenciuc (Contributor)
  • Amir Snapir (Contributor)
  • Toni Sarapohja (Contributor)
  • Matthew Smith (Contributor)

Aktiviteetti: Konferenssiesitelmä

Description

Contributors: Fizazi, Karim Shore, Neal Tammela, Teuvo Ulys, Albertas Vjaters, Egils Polyakov, Sergey Jievaltas, Mindaugas Luz, Murilo Alekseev, Boris Kuss, Iris Le Berre, Marie-Aude Petrenciuc, Oana Snapir, Amir Sarapohja, Toni Smith, Matthew / 2020 ASCO Virtual Scientific Program J Clin Oncol 38: 2020 (suppl; abstr 5514)10.1200/JCO.2020.38.15_suppl.5514
Aikajakso29 toukok. 2020
Tapahtuman otsikko2020 ASCO Annual Meeting
Tapahtuman tyyppiOther
Tunnustuksen arvoInternational